Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Around 10% Price Reduction to Have Big Impact on Firms
March 25, 2002
- NID to Develop Product Information System "Drug Store Navi"
March 25, 2002
- Highest Price Reduction Rate Was 78.4%
March 25, 2002
- DIAGNOSTIC NEWS IN BRIEF
March 25, 2002
- BUSINESS NEWS IN BRIEF
March 25, 2002
- MEDICAL DEVICE NEWS IN BRIEF
March 25, 2002
- Nippon Shinyaku Completes Renovation of Production Lines
March 25, 2002
- REGULATORY NEWS IN BRIEF
March 25, 2002
- Supply of Good-quality Drug Information Should Be Promoted: JPMA Seminar
March 25, 2002
- Objective of Immediate PMS Is to Promote Proper Use of Drugs: JAPIC Seminar
March 25, 2002
- JPMA, CROs, SMOs to Jointly Solve Problems with Clinical Trials
March 25, 2002
- Simvastatin Inhibits Coronary Events in 3-lipid Abnormality Group: Banyu Seminar
March 25, 2002
- Sankyo, Yamanouchi Explain Genomics Strategies: Nomura Bio Conference 2002
March 25, 2002
- AstraZeneca's Development Capability in Japan at Int'l Level: R&D Executives
March 25, 2002
- WORLD NEWS IN BRIEF
March 25, 2002
- New NHI Prices to Be Effective on April 1
March 18, 2002
- Pravastatin Is Beneficial for Postmenopausal Hyperlipidemia: Seminar
March 18, 2002
- Korosho's PAL Amendment Bill Approved by LDP
March 18, 2002
- Evidence-Based Infection Control GL Established
March 18, 2002
- Sales of Bonalon Remain at 60% of Target
March 18, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…